دورية أكاديمية
Virtual platelet cross-matching as transfusion management for patients with immune platelet refractoriness.
| العنوان: | Virtual platelet cross-matching as transfusion management for patients with immune platelet refractoriness. |
|---|---|
| المؤلفون: | Bonet-Bub C; Hospital Israelita Albert Einstein, São Paulo, Brazil., Blanco BP; Hospital Israelita Albert Einstein, São Paulo, Brazil., de Oliveira TC; Hospital Israelita Albert Einstein, São Paulo, Brazil., Sampaio TB; Hospital Israelita Albert Einstein, São Paulo, Brazil., Gomes I; Hospital Israelita Albert Einstein, São Paulo, Brazil., de Freitas Dutra V; Hospital Israelita Albert Einstein, São Paulo, Brazil., Costa TH; Hospital Israelita Albert Einstein, São Paulo, Brazil., Kutner JM; Hospital Israelita Albert Einstein, São Paulo, Brazil. |
| المصدر: | Vox sanguinis [Vox Sang] 2024 Mar; Vol. 119 (3), pp. 272-276. Date of Electronic Publication: 2023 Dec 05. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Science Country of Publication: England NLM ID: 0413606 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0410 (Electronic) Linking ISSN: 00429007 NLM ISO Abbreviation: Vox Sang Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2001- : Oxford, UK : Blackwell Science Original Publication: Basel : Karger |
| مواضيع طبية MeSH: | Blood Platelets* , Thrombocytopenia*, Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Blood Transfusion ; Platelet Transfusion ; HLA Antigens ; Histocompatibility Antigens Class I |
| مستخلص: | Background and Objectives: This study describes the use of the Epvix platform for virtual cross-matching (VC) of human leucocyte antigen (HLA)-compatible platelets for patients with immune platelet refractoriness, and demonstrates effectiveness of the selected platelets. Materials and Methods: A prospective cohort of haematological patients was evaluated from 2018 to 2022. HLA-typed donor bank profile was previously uploaded to the Epvix platform. Each patient's antibody reactivity panel (PRA) was included in the platform. Then, search, selection and VC were performed, and 24-h-corrected count increment (CCI) platelet transfusion was calculated (reference ≥2500). Results: Six patients were included (four female, two male), with mean age of 61 years. HLA antibodies were detected as the cause of immunity for all patients, whereas four patients also had non-immune causes. High percentage of alloimmunization was detected in all studied patients (mean PRA: 85.7%). Thirty different donors were able to schedule and perform platelet donations. The mean 24-h CCI count was 9882. All platelet transfusions achieved a satisfactory CCI count except for two transfusion events. Presence of non-immune causes identified in these two cases could account for the unsatisfactory CCI. Conclusion: Epvix is a free application hosted on the Web and uses the HLAMatchmaker algorithm to generate histocompatibility reports. This study demonstrates the efficiency of VC performed by Epvix. However, physical cross-matching will still be necessary in some instances, as the platform does not support human platelet antigen polymorphism. (© 2023 International Society of Blood Transfusion.) |
| References: | Chapman JM, Wendt L, Knudson CM. Comparison of platelet antibody screen, crossmatching and HLA antibody testing in patients refractory to platelet transfusions. Transfus Apher Sci. 2023;62:103622. Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets “mismatched” for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol. 1977;2:219-226. Duquesnoy RJ. HLAMMATCHMAKER: a molecularly based donor selection algorithm for highly alloimmunized patients. Transplant Proc. 2001;33:493-497. Filho HLAS, da Mata Sousa LCD, de Queiroz Carrascosa von Glehn C, da Silva AS, de Alcântara dos Santos Neto P, do Nascimento F, et al. EpHLA software: a timesaving and accurate tool for improving identification of acceptable mismatches for clinical purposes. Transpl Immunol. 2012;26:230-234. Anunciação FAC, da Mata Sousa LCD, da Silva AS, Marroquim MSC, Coelho AGB, Willcox GH, et al. EpViX: a cloud-based tool for epitope reactivity analysis and epitope virtual crossmatching to identify low immunologic risk donors for sensitized recipients. Transpl Immunol. 2015;33:153-158. Bub CB, Gonçalez AC, Barjas-Castro ML, Sousa LCDM, do Monte SJH, Castro V. The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness. Vox Sang. 2016;110:70-78. Pai S-C, Lo S-C, Lin Tsai S-J, Chang J-S, Lin D-T, Lin K-S, et al. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion. 2010;50:2318-2327. Marsh JC, Stanworth SJ, Pankhurst LA, Kallon D, Gilbertson AZ, Pigden C, et al. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial. Blood. 2021;137:310-322. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012;79:237-245. Nambiar A, Duquesnoy RJ, Adams S, Zhao Y, Oblitas J, Leitman S, et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood. 2006;107:1680-1687. Song X, Qi J, Fang K, Li X, Han Y. A meta-analysis of risk factors associated with platelet transfusion refractoriness. Int J Hematol. 2023;117:863-875. |
| فهرسة مساهمة: | Keywords: HLA antibodies; eplets; immune platelet refractoriness; platelet transfusion |
| المشرفين على المادة: | 0 (HLA Antigens) 0 (Histocompatibility Antigens Class I) |
| تواريخ الأحداث: | Date Created: 20231205 Date Completed: 20240314 Latest Revision: 20240314 |
| رمز التحديث: | 20240314 |
| DOI: | 10.1111/vox.13565 |
| PMID: | 38050782 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!